Take Advantage of Vaxart’s Sharp Pullback, Says Analyst

The recent news of an adverse reaction suffered by a participant in AstraZeneca’s Covid-19 vaccine candidate’s clinical trial demonstrated that getting an approved vaccine to market is no straight forward matter. What the unfortunate event also shows, is that the race to be first across the finish line with a viable solution is far from over.The field is still open, then, for vaccine specialist Vaxart (VXRT) to make its mark. The small cap is still far behind other major players in the development of its COVID-19 vaccine program, but following the publication of promising pre-clinical trial data, B Riley FBR …read more

Source:: Yahoo Finance

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.